Drug Profile
Immune modulation therapy-graft-versus-host disease - Vasogen
Alternative Names: VAS 981Latest Information Update: 23 Apr 2008
Price :
$50
*
At a glance
- Originator Vasogen
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Graft-versus-host disease
Most Recent Events
- 07 Jan 2004 No development reported - Preclinical for Graft-versus-host disease in Canada (unspecified route)
- 31 Mar 2000 Health Canada has given approval for initiation of a clinical trial in patients with leukaemia
- 23 Aug 1999 Preclinical development for Graft-versus-host disease in Canada (Unknown route)